HYGROTON
LOE ApproachingNDAORALTABLETPriority Review
Approved
Apr 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYGROTON is an oral small-molecule tablet approved in 1960 for an undisclosed indication. The generic name and mechanism of action are not specified in available data. Given the 1960 approval date and tablet formulation, it is likely a legacy therapeutic used in chronic disease management.
LOE Approaching
Moderate competitive pressure (30/100) suggests market erosion; brand teams are likely focused on defensive positioning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
HYGROTON offers limited career growth opportunity as a legacy product approaching loss of exclusivity with zero linked job openings. Roles available focus on defensive commercial strategies, cost optimization, and market retention rather than innovation or expansion.
Brand Manager (legacy product oversight)Field Sales Representative
Worked on HYGROTON at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.